首页> 外文期刊>AJR: American Journal of Roentgenology : Including Diagnostic Radiology, Radiation Oncology, Nuclear Medicine, Ultrasonography and Related Basic Sciences >Utility of diffusional kurtosis imaging as a marker of adverse pathologic outcomes among prostate cancer active surveillance candidates undergoing radical prostatectomy.
【24h】

Utility of diffusional kurtosis imaging as a marker of adverse pathologic outcomes among prostate cancer active surveillance candidates undergoing radical prostatectomy.

机译:扩散峰度成像在进行前列腺癌根治性切除术的前列腺癌积极监测候选人中作为不良病理结局指标的效用。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE. The purpose of this study was to compare findings at nongaussian diffusional kurtosis imaging and conventional diffusion-weighted MRI as markers of adverse pathologic outcomes among prostate cancer patients who are active surveillance candidates and choose to undergo prostatectomy. MATERIALS AND METHODS. Fifty-eight active surveillance candidates (prostate-specific antigen concentration, < 10 ng/mL; clinical tumor category less than T2a; Gleason score, 3 + 3; ≤ 25% of biopsy cores positive for tumor; ≤ 50% tumor involvement of any individual core; ≤ 20% tumor involvement across all cores) who underwent prostatectomy and preoperative 3-T MRI including diffusional kurtosis imaging (b values, 0, 500, 1000, 1500, and 2000 s/mm(2)) were included. Adverse pathologic features at prostatectomy were defined using two schemes of varying stringency. One scheme (less stringent) was presence of a Gleason score greater than 6 or extracapsular extension (n = 19). The other scheme (more stringent) was presence of a Gleason score greater than 6, extracapsular extension, or an index tumor 10 mm or larger (n = 35). Parametric maps displaying standard apparent diffusion coefficient (ADC), kurtosis (K) representing nongaussian diffusion behavior, and diffusion (D) representing a diffusion coefficient adjusted for nongaussian (kurtosis) behavior were reviewed, and the most abnormal region was recorded for each metric. Associations between these metrics and the presence of adverse final pathologic findings were assessed with unpaired Student t tests and receiver operating characteristic analyses. RESULTS. For both schemes, only D was significantly lower in patients with adverse final pathologic findings (p = 0.006, p = 0.025). K tended to be greater in patients with adverse final pathologic findings for the more stringent scheme (p = 0.072). ADC was not significantly different in the presence of adverse final pathologic findings for either scheme (p = 0.357, p = 0.383). With either scheme, D had a larger area under the receiver operating characteristics curve (AUC) for predicting adverse final pathologic results (AUC, 0.691 and 0.743) than did ADC (AUC, 0.569 and 0.655) or K (AUC, 0.617 and 0.714), but the difference was not significant (p = 0.183, p = 0.734). CONCLUSION. Preliminary results suggest that diffusional kurtosis imaging findings may have more value than findings at conventional diffusion-weighted MRI as a marker of adverse final pathologic outcome among active surveillance candidates.
机译:目的。这项研究的目的是比较非高斯扩散峰度成像和常规扩散加权MRI作为前列腺癌患者的不良病理结果的标志,这些前列腺癌患者是积极的监测候选人并选择进行前列腺切除术。材料和方法。 58名主动监测候选者(前列腺特异性抗原浓度,<10 ng / mL;临床肿瘤类别低于T2a;格里森评分,3 + 3;≤25%的活检核心为阳性;≤50%的肿瘤受累个体核心;所有核心≤20%的肿瘤受累)接受前列腺切除术和术前3-T MRI包括扩散峰度成像(b值分别为0、500、1000、1500和2000 s / mm(2))。使用两种严格程度不同的方案定义前列腺切除术的不良病理特征。一种方案(较不严格)是存在格里森评分大于6或囊外扩张(n = 19)。另一种方案(更严格)是存在格里森评分大于6,囊外扩张或索引肿瘤10毫米或更大(n = 35)。审查了显示标准表观扩散系数(ADC),代表非高斯扩散行为的峰度(K)和代表针对非高斯(峰态)行为调整的扩散系数的扩散(D)的参数图,并记录了每个指标的最不正常区域。这些指标与不良最终病理结果的存在之间的关联性通过未配对的学生t检验和接受者操作特征分析进行评估。结果。对于这两种方案,只有在最终病理结果不良的患者中D显着降低(p = 0.006,p = 0.025)。对于采用更严格方案的最终病理结果不利的患者,K值往往更高(p = 0.072)。两种方案在存在不利的最终病理结果时,ADC均无显着差异(p = 0.357,p = 0.383)。无论采用哪种方案,与ADC(AUC,0.569和0.655)或K(AUC,0.617和0.714)相比,D在接收器工作特性曲线(AUC)下具有更大的面积来预测不利的最终病理结果(AUC,0.691和0.743)。 ,但差异不显着(p = 0.183,p = 0.734)。结论。初步结果表明,扩散峰度成像的发现可能比常规扩散加权MRI的发现具有更大的价值,可作为主动监测候选人中不良最终病理结果的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号